about
Pharmacological interventions for clozapine-induced sinus tachycardiaPharmacological interventions for clozapine-induced hypersalivationPharmacological interventions for clozapine-induced hypersalivationPharmacological interventions for clozapine-induced sinus tachycardiaRare and very rare adverse effects of clozapineOptimising plasma levels of clozapine during metabolic interactions: a review and case report with adjunct rifampicin treatmentClozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003An analysis of QTc prolongation with atypical antipsychotic medications and selective serotonin reuptake inhibitors using a large ECG record database.A current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data.Antipsychotic pharmacotherapy and orthostatic hypotension: identification and management.Unrecognized clozapine-related constipation leading to fatal intra-abdominal sepsis - a case report.Ivabradine, a novel treatment for clozapine-induced sinus tachycardia: a case series.Clozapine-induced hypersalivation.Euglycemic clamp study in clozapine-induced diabetic ketoacidosis.A five year follow-up study of the use of clozapine in community practice.Serum clozapine levels: a review of their clinical utility.From chlorpromazine to clozapine--antipsychotic adverse effects and the clinician's dilemma.Risk factors for ileus in patients with schizophrenia.Clozapine prescribing in the UK: views and experience of consultant psychiatrists.Electroconvulsive Therapy Added to Non-Clozapine Antipsychotic Medication for Treatment Resistant Schizophrenia: Meta-Analysis of Randomized Controlled Trials.An update of safety of clinically used atypical antipsychotics.Augmentation of olanzapine in treatment-resistant schizophrenia.Emerging treatments for bipolar disorder: safety and adverse effect profiles.Clozapine-induced sialorrhea: pathophysiology and management strategies.Monitoring the safe use of clozapine: a consensus view from Victoria, Australia.Pharmacotherapy of Co-Occurring Schizophrenia and Substance Use DisordersCharacterization and clinical management of clozapine-induced fever.Choice of randomization to clozapine versus other second generation antipsychotics in the CATIE schizophrenia trialClozapine-induced bowel infarction: a case reportNeuroleptic malignant syndrome: an easily overlooked neurologic emergency.Pharmacological treatment of schizophrenia.Reintroduction of clozapine after perforation of the large intestine--a case report and review of the literature.A successful treatment strategy for clozapine-induced parotid swelling: a clinical case and systematic review.Adverse effects of clozapine in older patients: epidemiology, prevention and management.A state-wide quality improvement system utilising nurse-led clinics for clozapine management.Stercoral colitis mimicking appendicitis.Discontinuation of clozapine: a 15-year naturalistic retrospective study of 320 patients.Reason for clozapine cessation.Clozapine induced supra ventricular tachycardia.Increases in C-reactive protein may predict recurrence of clozapine-induced fever.
P2860
Q24187704-990A45AB-69E5-4206-9ECD-F67275D40209Q24242126-0657F2D3-4E77-427F-A8E4-FAEB4D558E0CQ24245171-ABE940DF-FB98-4B4C-A139-50B9F4514F27Q26471506-00F79ACB-DC35-4C06-9047-4D9C923511F0Q26798339-AF054589-2E1E-470F-8A4B-9F215D02185CQ26799098-D07683A3-6955-4C15-9E82-61DD7BE51695Q28281037-E12724CA-1970-4AFD-AAC1-25BD72B0A022Q30489429-8E83808E-DFC2-4806-8E4B-74C7AC1ECB8FQ30667146-884B3B90-E14C-4226-AD29-287A8CF37BA0Q33160283-8BE1F348-64F2-4C1D-B4A6-7A0B3B985255Q33166261-A4F6EB3F-D5BB-4F58-80A8-EDE8EF0B3092Q33937346-25AD864D-E300-40A7-81A1-A146DA8AC628Q33941959-60CAAFDD-6A03-4D85-89C1-3DD933AFC26AQ34449430-71EC180C-EA99-4A6C-9361-143DE1301596Q34983346-C4FAFE24-8974-477B-88E2-BC9DF16A8873Q35180807-612F8BDB-91E1-4004-B83F-031CED485ECAQ35633701-69B3655D-7A51-4D83-816B-D837032F55E0Q35898751-D434B2D8-D58A-45D4-ABDC-46BD97E8154AQ35906545-5417700D-9CAF-41A4-97E0-4E41EE3822EBQ36048418-F1EBCB97-D3E0-4394-ADFE-5531F850D337Q36062184-BCAFB821-9AA4-4E7E-8B3E-6C605CFABE81Q36331244-DD173954-23A9-4033-91C0-F43FBE27100BQ36364980-68821D5E-10F6-4A75-87E9-D3B04C80F3EBQ36412431-C9883251-1EC3-401C-A9CD-ABFE4B3FCB95Q36729613-64929587-98DD-4881-A006-A949B5A38933Q36927085-E36997D3-07D0-4352-831F-15A3E0D30ACBQ36929183-A1D99FC6-FF51-46D5-9A1A-B18999758E17Q37212118-5283D04F-83E9-469B-B961-ED343C818D47Q37285391-1A61B1B9-F1A0-4AFD-82B2-4164CAE28154Q37596135-6592209F-B551-4521-8F8D-AEC3C48B89DDQ38051438-D9E1942D-F405-45F7-A094-B573CB674FC0Q38113770-06AB5629-15E9-4321-B1E0-49267EF705FCQ38132166-D0DA0B1F-E5BC-42D2-9CC7-FA4EB71634A6Q38171350-912862B8-BAC5-4878-9055-C8507D861BE1Q38210463-DC09027E-5D8F-4530-9345-E837A9E49AB7Q39144864-AD3DB1FD-C642-43A5-9741-00446794CB31Q39302471-21CAF5B1-B015-4555-9A3C-D9A2209CBBDEQ39694991-9ECB0B88-B9A7-4A8C-9B49-F4B515CCE0A4Q40216319-FD82E483-B1BF-4EFF-AA75-289917B9F4B6Q40400167-5FABE4FB-51B3-466F-807C-B8FA75D03D13
P2860
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
Management of the adverse effects of clozapine.
@en
Management of the adverse effects of clozapine.
@nl
type
label
Management of the adverse effects of clozapine.
@en
Management of the adverse effects of clozapine.
@nl
prefLabel
Management of the adverse effects of clozapine.
@en
Management of the adverse effects of clozapine.
@nl
P2093
P1476
Management of the adverse effects of clozapine.
@en
P2093
P304
P356
10.1093/OXFORDJOURNALS.SCHBUL.A033333
P407
P577
1998-01-01T00:00:00Z